Sequence Symmetric Modified IgG4 Bispecific Antibodies
    66.
    发明申请
    Sequence Symmetric Modified IgG4 Bispecific Antibodies 审中-公开
    序列对称修饰的IgG4双特异性抗体

    公开(公告)号:US20150018529A1

    公开(公告)日:2015-01-15

    申请号:US14380309

    申请日:2013-02-22

    Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.

    Abstract translation: 本公开涉及类IgG4的对称双特异性抗体,其包含两个重链,每个重链各自包含可变结构域,CH1结构域和铰链区,其中在每个重链中:形成链间二硫键的CH1结构域中的半胱氨酸 与轻链中的半胱氨酸键合被另一个氨基酸取代; 并且任选地位于上部铰链区域中的一个或多个氨基酸被半胱氨酸取代,其中每个重链的恒定区序列相似或相同,并且每个重链中的可变区不同,包含其的制剂, 使用上述各项进行治疗和制备所述抗体和制剂的方法。

    Sequence Asymmetric Modified IgG4 Bispecific Antibodies
    67.
    发明申请
    Sequence Asymmetric Modified IgG4 Bispecific Antibodies 有权
    序列不对称修饰的IgG4双特异性抗体

    公开(公告)号:US20150017169A1

    公开(公告)日:2015-01-15

    申请号:US14380310

    申请日:2013-02-22

    Abstract: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterised in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation.

    Abstract translation: 本公开提供了包含两个重链或重链片段的不对称混合抗体,其各自包含至少一个可变区,铰链区和CH1结构域,其中第一重链或其片段是IgG4类,并且具有: 在CH1结构域中根据Kabat编号系统编号的位置127处的链半胱氨酸被另一个氨基酸取代; 并且b任选地一个或多个位于上部铰链区域的氨基酸被半胱氨酸取代,并且其中第二重链或其片段的特征在于部分或全部链具有与所述第一重质 至少在可变区域外的区域(例如,恒定区域),包含上述两者的治疗剂,以及用于制备抗体和制剂的方法。

    ALBUMIN BINDING ANTIBODIES AND BINDING FRAGMENTS THEREOF
    70.
    发明申请
    ALBUMIN BINDING ANTIBODIES AND BINDING FRAGMENTS THEREOF 有权
    ALBUMIN BINDING抗体及其结合片段

    公开(公告)号:US20140302033A1

    公开(公告)日:2014-10-09

    申请号:US14356181

    申请日:2012-11-09

    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.

    Abstract translation: 1.一种血清白蛋白结合抗体或其片段,其包含具有SEQ ID NO:1或SEQ ID NO:2中给出的序列的重链可变结构域和/或包含具有SEQ ID NO:3中给出的序列的轻链可变区或 SEQ ID NO:4,特别包括具有SEQ ID NO:1和SEQ ID NO:3中给出的序列的重链可变结构域和轻链可变区或重链可变结构域和具有 SEQ ID NO:2和SEQ ID NO:4中给出的序列。 本公开还延伸到编码抗体或片段的多核苷酸,包含其的载体和能够表达多核苷酸的宿主细胞。 本公开还包括药物组合物,其包含使用其中任何一种的抗体或片段和治疗剂。

Patent Agency Ranking